Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers

Sheldon H. Preskorn, David J. Greenblatt, David Flockhart, Yan Luo, Elke S. Perloff, Jerold S. Harmatz, Bryan Baker, Alisa Klick-Davis, Zeruesenay Desta, Tal Burt

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female participants. The outcome measures were changes in metoprolol peak plasma levels, area under the plasma concentration-time curve, and clearance. The results were tested using paired t tests and independent t tests. The addition of each drug produced statistically significant changes in metoprolol pharmacokinetics. The rank order for the change in metoprolol area under the plasma concentration-time curve was duloxetine (180%) > escitalopram (89%) > sertraline (48% and 67%). Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume27
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Sertraline
Cytochrome P-450 CYP2D6
Citalopram
Metoprolol
Healthy Volunteers
Pharmacokinetics
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Duloxetine Hydrochloride
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. / Preskorn, Sheldon H.; Greenblatt, David J.; Flockhart, David; Luo, Yan; Perloff, Elke S.; Harmatz, Jerold S.; Baker, Bryan; Klick-Davis, Alisa; Desta, Zeruesenay; Burt, Tal.

In: Journal of Clinical Psychopharmacology, Vol. 27, No. 1, 02.2007, p. 28-34.

Research output: Contribution to journalArticle

Preskorn, SH, Greenblatt, DJ, Flockhart, D, Luo, Y, Perloff, ES, Harmatz, JS, Baker, B, Klick-Davis, A, Desta, Z & Burt, T 2007, 'Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers', Journal of Clinical Psychopharmacology, vol. 27, no. 1, pp. 28-34. https://doi.org/10.1097/00004714-200702000-00005
Preskorn, Sheldon H. ; Greenblatt, David J. ; Flockhart, David ; Luo, Yan ; Perloff, Elke S. ; Harmatz, Jerold S. ; Baker, Bryan ; Klick-Davis, Alisa ; Desta, Zeruesenay ; Burt, Tal. / Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. In: Journal of Clinical Psychopharmacology. 2007 ; Vol. 27, No. 1. pp. 28-34.
@article{81541087478d4b41bfd6edc0aebb967e,
title = "Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers",
abstract = "This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female participants. The outcome measures were changes in metoprolol peak plasma levels, area under the plasma concentration-time curve, and clearance. The results were tested using paired t tests and independent t tests. The addition of each drug produced statistically significant changes in metoprolol pharmacokinetics. The rank order for the change in metoprolol area under the plasma concentration-time curve was duloxetine (180{\%}) > escitalopram (89{\%}) > sertraline (48{\%} and 67{\%}). Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different.",
author = "Preskorn, {Sheldon H.} and Greenblatt, {David J.} and David Flockhart and Yan Luo and Perloff, {Elke S.} and Harmatz, {Jerold S.} and Bryan Baker and Alisa Klick-Davis and Zeruesenay Desta and Tal Burt",
year = "2007",
month = "2",
doi = "10.1097/00004714-200702000-00005",
language = "English",
volume = "27",
pages = "28--34",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers

AU - Preskorn, Sheldon H.

AU - Greenblatt, David J.

AU - Flockhart, David

AU - Luo, Yan

AU - Perloff, Elke S.

AU - Harmatz, Jerold S.

AU - Baker, Bryan

AU - Klick-Davis, Alisa

AU - Desta, Zeruesenay

AU - Burt, Tal

PY - 2007/2

Y1 - 2007/2

N2 - This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female participants. The outcome measures were changes in metoprolol peak plasma levels, area under the plasma concentration-time curve, and clearance. The results were tested using paired t tests and independent t tests. The addition of each drug produced statistically significant changes in metoprolol pharmacokinetics. The rank order for the change in metoprolol area under the plasma concentration-time curve was duloxetine (180%) > escitalopram (89%) > sertraline (48% and 67%). Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different.

AB - This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol. Single-dose pharmacokinetics of metoprolol were measured before and after 17 days of treatment with escitalopram 20 mg/d, duloxetine 60 mg/d, or sertraline 100 mg/d in young healthy male and female participants. The outcome measures were changes in metoprolol peak plasma levels, area under the plasma concentration-time curve, and clearance. The results were tested using paired t tests and independent t tests. The addition of each drug produced statistically significant changes in metoprolol pharmacokinetics. The rank order for the change in metoprolol area under the plasma concentration-time curve was duloxetine (180%) > escitalopram (89%) > sertraline (48% and 67%). Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different.

UR - http://www.scopus.com/inward/record.url?scp=33846210546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846210546&partnerID=8YFLogxK

U2 - 10.1097/00004714-200702000-00005

DO - 10.1097/00004714-200702000-00005

M3 - Article

C2 - 17224709

AN - SCOPUS:33846210546

VL - 27

SP - 28

EP - 34

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -